Human psychopharmacology
-
Human psychopharmacology · Mar 2013
Randomized Controlled Trial Multicenter Study Controlled Clinical TrialEfficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
Anxiety in major depression is associated with increased morbidity. The antidepressant, agomelatine, which acts as an agonist at melatonin MT(1) and MT(2) receptors and as an antagonist at serotonin 5-HT(2C) receptors, has demonstrated efficacy and safety in both major depression and generalized anxiety disorder. Here, we investigated the efficacy of agomelatine in anxious depression. ⋯ Once-a-day oral agomelatine is a new, efficacious alternative option for the treatment of anxiety in patients with major depression.